US Food and Drug Administration Approval of Addyi (Flibanserin) for Treatment of Hypoactive Sexual Desire Disorder
palbociclib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Before using flibanserin
nifedipinenifedipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nisoldipinenisoldipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nisoldipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nitrous oxidenitrous oxide and flibanserin both increase sedation.
Interactions with Food/Tobacco/Alcohol
nitrous oxide and flibanserin both increase sedation. nizatidinenizatidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nizatidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. olanzapineolanzapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, olanzapine. paroxetineparoxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. paroxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Aspect | Explanation |
|---|---|
| Serotonin Receptor Modulation | Acts as a 5-HT1A receptor agonist and 5-HT2A antagonist |
| Effect on Neurotransmitters | Balances serotonin, dopamine, and norepinephrine activity |
| Impact on Sexual Desire | Enhances desire by modulating serotonergic inhibition of dopamine pathways |
pazopanibpazopanib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pazopanib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- The prescribing guidelines emphasize cautious use in women on other psychotropic drugs.
- Flibanserin's approval was driven by a need for female-specific sexual health medications.
- Its mechanism involves serotonergic pathways impacting sexual response.
- The drug is typically part of a broader therapy including counseling or therapy.
- Studies indicate a small but statistically significant benefit for some women.
- It is important to rule out other medical or psychological causes before use.
- Flibanserin is contraindicated with certain medications, such as CYP3A4 inhibitors.
- Side effect management includes monitoring blood pressure and mental status.
- The medication's role is to improve quality of life by addressing sexual desire challenges.
pentamidinepentamidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentamidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Gold | 100 mg | 84 + 6 Pills | 264.44€ 251.85€ | |
| Kamagra Polo | 100 mg | 12 Pills | 60.21€ 57.34€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Cialis Generic | 60mg | 270 + 10 Pills | 443.96€ 422.82€ | |
| Super Kamagra | 160 mg | 20 + 4 Pills | 155.35€ 147.95€ | |
| Cialis Generic | 2.5mg | 60 + 4 Pills | 83.43€ 79.46€ | |
| Cialis Generic | 40mg | 10 Pills | 37.79€ 35.99€ | |
| Viagra Professional | 100mg | 120 + 4 Pills | 262.83€ 250.31€ | |
| Kamagra 100 mg | 100 mg | 360 + 6 Pills | 839.95€ 799.95€ | |
| Kamagra Gold | 50 mg | 120 + 6 Pills | 281.13€ 267.74€ |
pentobarbitalpentobarbital will decrease the level buy cenforce 120mg or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Strong CYP3A4 inducers substantially decrease flibanserin systemic exposure.pentobarbital and flibanserin both increase sedation. pentobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pilocarpinepilocarpine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pilocarpine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Reward Processing as a Symptom Dimension in Psychiatric Disorders
mitoxantrone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. modafinilmodafinil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. modafinil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. nafcillinnafcillin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nafcillin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Drug Interactions Table
naldemedineflibanserin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. Monitor naldemedine for potential adverse effects if coadministered with P-gp inhibitors. flibanserin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. nevirapinenevirapine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pimozidepimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, pimozide.
Helping Veterans stay well and well-informed
olanzapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. omeprazoleomeprazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Coadministration of flibanserin with strong CYP2C19 inhibitors may increase flibanserin exposure and increase the risk of hypotension, syncope, and CNS depression.omeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. omeprazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. orphenadrineorphenadrine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Before taking flibanserin,
orphenadrine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. oxybutyninoxybutynin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. oxybutynin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. oxybutynin transdermal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. palbociclibpalbociclib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pravastatinpravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- Flibanserin's development was rooted in attempts to find antidepressants with sexual side effects.
- It was repurposed as a treatment for female sexual desire disorder.
- The medication is available by prescription only.
- It belongs to the class of serotonergic drugs affecting brain chemistry.
- Women with liver disease should avoid taking flibanserin.
- The medication is primarily metabolized in the liver via CYP3A4.
- Flibanserin has been the subject of debates over its cost-benefit ratio.
- It is not approved for use in men or non-binary individuals.
- Clinical guidelines recommend using flibanserin only after other causes of low desire are addressed.
prednisoloneprednisolone will increase the level or effect of flibanserin by aldehyde dehydrogenase inhibition. prednisolone will increase the level or effect of flibanserin by aldehyde dehydrogenase inhibition. primaquineprimaquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primaquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidoneprimidone will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. progesterone micronizedprogesterone micronized will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Issue | Description |
|---|---|
| Efficacy Debate | Some experts question the clinical significance of benefits |
| Side Effect Concerns | Risks of hypotension, syncope, and severe allergic reactions |
| Marketing & Approval Controversies | Criticism over FDA approval process and marketing practices |
| Post-Marketing Surveillance | Ongoing monitoring for rare adverse events |
progesterone micronized will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. propofolpropofol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. propofol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. quinineflibanserin increases levels of quinine by P-glycoprotein (MDR1) efflux transporter. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin.quinine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. flibanserin increases levels of quinine by P-glycoprotein (MDR1) efflux transporter. rabeprazolerabeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Supplementary Material
mifepristonemifepristone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mirtazapinemirtazapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mirtazapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitapivatmitapivat decreases levels of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.
Lactation Precautions
Monitor patients for loss of therapeutic effect if taking sensitive CYP2C19 substrates. mitapivat decreases levels of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. mitotanemitotane will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitotane will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitoxantronemitoxantrone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rabeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ranolazineranolazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ranolazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Property | Description | Status |
|---|---|---|
| Approved Uses | Hypoactive Sexual Desire Disorder (HSDD) in women | Yes |
| Mechanism of Action | Serotonin receptor modulator | Partial agonist & antagonist |
| FDA Approval Year | 2015 | |
| Common Brand Name | Addyi |
rifabutin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampinrifampin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentinerifapentine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.